Clinical implications of midventricular obstruction and intravenous propranolol use in transient left ventricular apical ballooning (Tako-tsubo cardiomyopathy) - 09/08/11
, Kazufumi Tsuchihashi, MD, PhD a, Kazuhiko Nagao, MD, PhD b, Michifumi Kyuma, MD, PhD c, Hitoshi Ooiwa, MD, PhD d, Akihiko Nozawa, MD, PhD e, Shinya Shimoshige, MD a, Mariko Eguchi, MD, PhD a, Takeru Wakabayashi, MD, PhD a, Satoshi Yuda, MD, PhD a, Mamoru Hase, MD, PhD a, Tomoaki Nakata, MD, PhD a, Kazuaki Shimamoto, MD, PhD aRésumé |
Background |
Persistent hypotension with dynamic midventricular obstruction (MVO) in patients with transient left ventricular (LV) apical ballooning (Tako-tsubo cardiomyopathy) is an important complication that needs to be treated.
Purpose |
The objective of this study is to determine the effects of intravenous propranolol challenge on MVO in transient LV apical ballooning.
Subjects and Methods |
Thirty-four patients (12 males, 22 females, mean age 64 ± 17 years, age range 22-84 years) with LV apical ballooning were enrolled. The hemodynamic and echocardiographic effects of propranolol (0.05 mg/kg, maximum 4 mg) were analyzed in 13 patients.
Results |
(1) Midventricular obstruction was present in 8 (24%) of 34 patients, and the pressure gradient (PG) ranged from 28 to 140 mm Hg. (2) Patients with MVO had similar demographic and clinical characteristics (symptoms, peak creatine kinase, plasma catecholamine levels) as those without MVO; however, in patients with MVO, abnormal Q waves on electrocardiogram and hypotension were more prevalent. (3) In the MVO group, intravenous propranolol changed the PG from 90 ± 42 to 22 ± 9 mm Hg, the systolic blood pressure (SBP) from 85 ± 11 to 116 ± 20 mm Hg, and the LV ejection fraction (LVEF) from 30% ± 7% to 43% ± 4%. (4) In all subjects, the changes in the PG after propranolol injection had a significant linear correlation with the SBP and LVEF changes: ΔSBP = 4.738 + 0.315 × ΔPG (r = 0.689 (P < .001) and ΔLVEF = 2.973 + 0.1321 × ΔPG (r = 0.715, P < .001).
Conclusion |
Intravenous propranolol is useful for treating dynamic MVO in patients with transient LV apical ballooning.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported by research grants for cardiovascular disease (14C-1) from the Ministry of Health, Labour and Welfare, Tokyo, Japan. |
Vol 155 - N° 3
P. 526.e1-526.e7 - mars 2008 Retour au numéro
Article précédent
- Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications
- Joana Mascarenhas, Patrícia Lourenço, Ricardo Lopes, Ana Azevedo, Paulo Bettencourt
- Associations between neurohormonal and inflammatory activation and heart failure in children
- Christopher Ratnasamy, Daniel D. Kinnamon, Steven E. Lipshultz, Paolo Rusconi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?